Current potentialities of chemotherapy for hormone-resistant cancer of the prostate
https://doi.org/10.17650/1726-9776-2005-1-3-38-43
Abstract
The purpose of the study was to reveal the most optimal treatment of hormone-resistant prostatic cancer (HRPC), by comparatively analyzing the efficiency and toxicity of 4 chemotherapy regimens: 1) mitoxantrone, 12 mg/m2, i.v. once 21 days; prednisolone, 10 mg/day (MP); 2) mitoxantrone, 12 mg/m2, i.v. on day 2; cisplatin, 60 mg/m2, i.v. on day 1; prednisolone, 10 mg/day (MCP); 3) docetaxel, 75 mg/m2; estramustine, 300 mg/m2 daily; prednisolone, 10 mg/day (DEP); 4) doxorubicin, 20 mg/m2, on day 1 of weeks 1, 3, and 5; ketoconasole, 1200 mg/day on days 1—7 of weeks 1, 3, and 5; docetaxel, 20 mg/m2 on day 1 of weeks 2, 4, and 6; estramustine, 420 mg/day, on days 1—7 of weeks 2, 4, and 6; prednisolone, 10 mg/day (DKDEP). The study covering 39 patients indicated the low efficiency of MR (8,6%) as first-line chemotherapy for HRPC and the high efficiency of the docetaxel-induced regimens used mainly as second-line chemotherapy: DEP (40%) and DKDEP (30%). Treatment of HRPC was most effective when the docetaxel-containing combinations were administered. The latter may be used as first-line chemotherapy and second-line one after application of mitoxantrone-containing regimens.
About the Authors
B. P. Matveyev
ГУ РОНЦ им. Н.Н. Блохина РАМН
Russian Federation
Russian Federation
V. A. Gorbunova
ГУ РОНЦ им. Н.Н. Блохина РАМН
Russian Federation
Russian Federation
B. V. Bukharkin
ГУ РОНЦ им. Н.Н. Блохина РАМН
Russian Federation
Russian Federation
S. A. Kalinin
ГУ РОНЦ им. Н.Н. Блохина РАМН
Russian Federation
Russian Federation
References
1. Бухаркин Б.В. Лечение гормонорефрактерного рака предстательной железы // Матвеев Б.П. (ред.). Клиническая онкоурология. — М., 2003. — С. 593—596.
2. Graft N., Shostac Y., Carey M. et al. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase // Nature Med. — 1999. — Vol. 5, № 3. — P. 280—285.
3. Green S., Furr B. Prospects for the treatment of endocrine-responsive tumors // Endocr. Relat. Cancer. — 1999. — Vol. 6, № 3. — P. 349—371.
4. Lein M., Yung K., Dinh L.K. et al. Synthetic inhibitor of metalloproteinases (batimastat) reduces prostate cancer growth in an orthotopic rat model // Prostate. — 2000. — Vol. 43, № 2. — P. 77—82.
5. Petrylak D.P. Chemotherapy for advanced hormone refractory prostate cancer // Urology. — 1999. — Vol. 54. — P. 30—35.
6. Primo L.N., Meyers F.K. Treatment options in androgen-independent prostate cancer // Cancer Invest. — 1999. — Vol. 17, № 2. — P. 137—144.
7. Rosenthal M.A. Advances in the management of prostate cancer // Austral. & N.Z. J. Med. — 2000. — Vol. 30, № 5. — P. 593—599.
8. Tannock I.F., Osoba D., Stockier M.R. et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points // J. Clin. Oncol. — 1996. — Vol. 14 — P. 1756—1764.
9. Kantoff P.W., Halabi S., Conoway M. et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group В 9182 study // J. Clin. Oncol. — 1999. — Vol. 17. — P. 2506—2513.
10. Hudes G.R. Estramustine-based chemotherapy // Semin. Urol. Oncol. — 1997. — Vol. 15. — P. 13—19.
11. Haas N., Garay C., Roth B. et al. Weekly paclitaxel by 3 hour infusion plus oral estramustine in metastatic HRPC // Proc. Am. Soc. Clin. Oncol. — 1999. — Vol. 40. — P. 88 (Abstr. 340).
12. Hudes G.R., Nathan F., Khater C. et al. Phase II trial of 96 hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer // J. Clin. Oncol. — 1997. — Vol. 15. — P. 3156—3163.
13. Hudes G.R., Manola J., Convoy J. et al. Phase II study of weekly paclitaxel by 1-hour infusion plus reduced-dose oral estramustine in metastatic hormone-refractory prostate carcinoma: a trial of the Eastern Cooperative Oncology Group // Proc. Am. Soc. Clin. Oncol. — 2001. — Vol. 42. — P. 177 (Abstr. 697).
14. Kelly K., Gaudin P. Slovin S. et al. Paclitaxel, estramustine and carboplatin in patients with advanced prostate cancer // J. Urol. — 1999. — Vol. 161. — P. 174 (Abstr. 683).
15. Smith D.C., Esper P., Strawderman M. et al. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer // J. Clin. Oncol. — 1999. — 17, № 6. — P. 1664—1671.
16. Natale R., Zaretsky S. Phase I/II trial of estramustine and taxotere in patients with hormone refractory prostate cancer // Proc. Am. Soc. Clin. Oncol. — 1999. — Vol. 40. — P. 339 (Abstr. 1343).
17. Petrylak D.P., Macarthur R.B., О ‘Connor J. et al. Phase 1 trial of docetaxel with estramustine in androgen-independent prostate cancer // J. Clin. Oncol. — 1999. — Vol. 17. — P. 958—967.
18. Savarese D.M., Talpin M.E., Halabi S. et al. A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B. Trial 9780 // Semin. Oncol. — 1999. —Vol. 26. — P. 39—44.
19. Ellerhorst J.A., Tu S.M., Amato R.J. et al. Phase II trial of alternating weekly chemogormonal therapy for patients with androgen-independent prostate cancer // Clin. Cancer Res. — 1997. — Vol. 3. — P. 2371—2376.
20. Eisenberger M.A., De Vit R., Berry W. et al. A multicenter phase III comparison of docetaxel + prednisone and mitoxantrone + prednisone in patients with hormone-refractory prostate cancer // Proc. Am. Soc. Clin. Oncol. — 2004. — Vol. 45. — P. 5 (Abstr. 4).
21. Petrylak D.P., Tangen C., Hussain M. et al. SWOG 99-16: Randomized phase III trial of docetaxel/estramustine versus mitoxantrone/prednizolone in men with androgen independent prostate cancer // Proc. Am. Soc. Clin. Oncol. — 2004. — Vol. 45. — P. 5 (Abstr 3).
22. Yagoda A., Petrylak D. Cytotoxic chemotherapy for advanced hormone resistant prostate cancer // Cancer (Philad.). — 1993. — Vol. 71. — P. 1098—1109.
Review
For citations:
Matveyev B.P., Gorbunova V.A., Bukharkin B.V., Kalinin S.A. Current potentialities of chemotherapy for hormone-resistant cancer of the prostate. Cancer Urology. 2005;1(3):38-43. (In Russ.) https://doi.org/10.17650/1726-9776-2005-1-3-38-43
Views:
223
Email this article 